Table 1. The EGFR-KDD is a recurrent alteration.
| Dataset | Identification # | Age | Gender | Reported diagnosis |
|---|---|---|---|---|
| Foundation Medicine | FM-1 | 52 | Female | Lung adenocarcinoma |
| FM-2* | 33 | Male | Lung adenocarcinoma | |
| FM-3 | 53 | Female | Lung adenocarcinoma | |
| FM-4 | 57 | Female | Lung adenocarcinoma | |
| FM-5 | 29 | Female | Lung non-small cell lung cancer (NOS) | |
| FM-6 | 53 | Female | Brain astrocytoma | |
| FM-7 | 49 | Male | Brain glioblastoma | |
| FM-8 | 54 | Male | Brain glioblastoma | |
| FM-9 | 2 | Female | Kidney Wilms' tumor | |
| FM-10 | 63 | Female | Peritoneal serous carcinoma | |
| FM-11 | 27 | Female | Soft tissue sarcoma (NOS) | |
| TCGA | TCGA-49-4512 | 69 | Male | Lung adenocarcinoma |
| TCGA-12-0821 | 62 | Female | Brain glioblastoma | |
| MSKCC | MSKCC-1* | 33 | Male | Lung adenocarcinoma |
| MSKCC-2 | 67 | Female | Lung adenocarcinoma | |
| MSKCC-3† | 53 | Male | Brain glioblastoma |
Characteristics of EGFR-KDD exons 18–25 patients from Foundation Medicine, TCGA, and Memorial Sloan Kettering Cancer Center datasets. NOS = not otherwise specified.
*
= index patient.
†
= this patient's tumor also contained high level amplification of wild-type EGFR and an EGFR G719C mutation. The EGFR-KDD and EGFR G719C alterations were below the level of wild-type EGFR amplification, and presumably reflect sub-clonal populations.